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Abstract   
Background: Substance P (SP) is a pain- and inflammation-related neuropeptide 
which preferentially binds to the neurokinin receptor 1 (NK1). SP and NK1 receptors 
have been implicated in joint pain, inflammation and damage in animal models and 
human studies of osteoarthritis (OA). The aim of this study was to test if genetic 
variation at the neurokinin 1 receptor gene (TACR1) is associated with pain in 
individuals with radiographic knee OA. 
Methods: Participants from the Genetics of OA and Lifestyle study were used for the 
discovery group (n=1,615). Genotype data for six SNPs selected to cover most 
variation in the TACR1 gene were used to test for an association with symptomatic 
OA.. Replication analysis was performed using data from the Chingford 1,000 
Women Study, Hertfordshire Cohort Study, Tasmanian Older Adult Cohort Study and 
the Clearwater OA Study. In total n=1,715 symptomatic OA and n=735 
asymptomatic OA individuals were analysed. 
Results: Out of six SNPs tested in the TACR1 gene, one (rs11688000) showed a 
nominally significant association with a decreased risk of symptomatic OA in the 
discovery cohort. This was then replicated in four additional cohorts.  After adjusting 
for age, gender, body mass index and radiographic severity, the G (minor) allele at 
rs11688000 was associated with a decreased risk of symptomatic OA compared to 
asymptomatic OA cases (p=9.90x10-4, OR=0.79 95% 0.68-0.90 after meta-analysis). 
Conclusions: This study supports a contribution from the TACR1 gene in human OA 
pain, supporting further investigation of this gene’s function in OA. 
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Introduction 
Osteoarthritis (OA) is a major source of pain and disability, and yet many people with 
radiographic OA might be asymptomatic (Hunter et al. 2013). Radiographic change 
is weakly associated with OA pain,  indicating that OA pain is modulated by other 
mechanisms in addition structural damage (Hunter et al. 2013). OA pain variation 
between individuals might in part be due to genetic factors which influence pain 
sensitivity. 
Substance P is a pain- and inflammation-related neuropeptide found in the 
peripheral and central nervous system as part of the NK1 pain pathway. SP has been 
implicated in pain and swelling in OA (Marshall et al. 1990; Lindh et al. 1997). In one 
study, levels of SP were higher in the cerebrospinal fluid of individuals with painful 
OA versus control participants (Lindh et al. 1997). SP has also been reported to be 
elevated in synovial fluid from individuals with knee OA compared to controls 
(Marshall et al. 1990). 
SP preferentially binds to the neurokinin receptor 1 (NK1; also known as the 
tachykinin 1 receptor, TACR1). This receptor mediates the effects of SP. 
Research has linked the upregulation of SP and NK1 receptors (in response to 
catabolic growth factors) to accelerated matrix degradation in knee chondrocytes (Im 
et al. 2008) 
NK1 receptors have also been implicated in depression (Hallberg 2015). This is 
relevant to the study of pain and OA as low mood is associated with augmented 
central pain processing and worse self-reported pain in knee OA (de Luca et al. 
2016). 
These findings support a possible contribution of NK1 and SP to OA pain..  
Currently, research on genetic variants in the TACR1 gene has focused mostly on 
psychological and psychiatric conditions such as bipolar disorder, attention deficit 
hyperactivity disorder (ADHD) and alcohol dependence (Sharp et al. 2014, Yan et al. 
2010, Blaine et al. 2012).  For example the variant rs3771829 has been linked to 
both bipolar disorder and ADHD (Sharp et al. 2014, Yan et al. 2010). and the variant 
rs11688000 has been associated with alcohol dependence (Blaine et al. 2012). The 
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variant rs11688000 has been associated with alcohol dependence (Blaine et al. 
2012). Variants rs3771863, rs3755459 and rs1106855 on the other hand,  predict an 
activation response in response to alcohol cues (Blaine et al. 2012). 
The role variation in the TACR1 gene in pain has been less studied. Klestad et al 
(2011) failed to find any association between ten variants in the TACR1 gene and 
the mean opioid dose used for cancer pain patients. On the other hand, in an 
exploratory study Storm et al (2013) reported that variants in TACR1 were nominally 
associated with skin conductivity and clinical stress score responses to tetanic 
nociceptive stimuli under general anaesthesia suggesting that genetic variation in 
this receptor (along with beta arrestin, dopamine receptor D3, and P-glyc.oprotein) 
could be implicated in genetic predisposition to pain sensitivity although this study 
did not adjust for multiple testing. 
Based on the role of SP in OA pain and the likely involvement of genetic variation in 
nociceptive responses we hypothesized that genetic variations in TACR1 might 
contribute to pain sensitivity in knee OA. Our goal was to investigate variants in the 
SP receptor (TACR1) gene to test for an association with symptomatic OA but the 
variants in this gene studied to date have not been reported to have a clear 
functional role (e.g. binding affinity or expression levels).  We therefore investigated 
six variants that cover most of the variation in this gene and tested them for 
correlation with pain in individuals with radiographic OA damage. We then 
proceeded to validate this findings in independent cohorts of knee OA patients. 
 
 
Materials and Methods 
Study participants: 
The relevant research ethics committee or institutional review boards approved the 
study protocols for each of the five cohorts used in this study. For all participants, 
radiographic knee OA was defined as a Kellgren-Lawrence (K/L) grade ≥2 at the 
tibiofemoral compartment at one or both knees and controls were individuals with 
K/L <2. The GOAL study was used as a discovery cohort and data derived from the 
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Hertfordshire Cohort Study (HCS), the Chingford 1,000 Women study, the 
Tasmanian Older Adult Cohort (TASOAC) and the Clearwater Osteoarthritis Study 
(COS) were used for replication analysis. These cohorts have been described in 
detail previously (Valdes et al. 2011) and are summarised briefly  below and in Table 
1. 
Genetics of OA and Lifestyle (GOAL) Study (Discovery): Participants with clinically 
severe knee OA were recruited from hospital orthopaedic surgery lists were recruited 
for the cases in the Nottinghamshire-based GOAL study (previously described by 
Valdes et al. 2011). These individuals were used for the discovery group in this 
analysis, excluding individuals with hip OA but no knee OA. Individuals with current 
knee pain for 15 or more days of a month during the past year were classified as 
symptomatic knee OA cases. Individuals without such pain were classified as 
asymptomatic knee OA cases. Control participants were recruited from a urology 
clinic at the same hospital and had no knee symptoms. If radiographic knee OA was 
found in these individuals, they were classified as asymptomatic OA. X rays were 
scored by a single observer using K/L grades for each knee joint. Approval was 
obtained from the research ethics committees of Nottingham City Hospital and North 
Nottinghamshire. Information about depression as a comorbidity was obtained via 
the use of a questionnaire, which asked individuals if they had ever been diagnosed 
with this condition. 
Hertfordshire Cohort Study (HCS): This is a large, population-based study and has 
been previously described (Aihie Sayer et al. 2011). Ethical approval was obtained 
from East and North Hertfordshire ethical committees. Men and women were 
recruited and attended a clinic for further investigation; a subgroup underwent knee 
X-rays. Individuals with K/L≥2 at the tibiofemoral compartment of one or both knees 
were included and were classified as having painful OA if they reported pain on most 
days in the last month. 
Chingford 1,000 Women Study: This study is a prospective population-based 
longitudinal cohort, including women derived from the register of a large general 
practice in North London. The study design and rationale are described by Hart et al. 
1993. The Guy’s St. Thomas’ Trust and the local ethics committee approved the 
study and written consent was obtained from each woman (Outer North East London 
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Research Ethics Committee (formerly Barking & Havering and Waltham Forest 
RECs), LREC (R&WF) 96). Radiographic knee OA was classified using standard X-
rays of weight-bearing knees (anteroposterior view only) and was defined as K/L≥2 
at either knee. Symptomatic knee OA was defined as pain in the knee most days of 
a month over the past year. The pain data used here was assessed at the time of the 
10 year X ray and follow-up. Controls were classified based on the absence of 
radiographic knee OA regardless of pain status. 
Tasmanian Older Adult Cohort (TASOAC) Study: This study is an ongoing, 
prospective, population-based study which started in 2002. This study is aimed at 
identifying environmental, genetic and biochemical factors associated with the 
development and progression of OA. Subjects between the ages of 50 and 80 years 
were randomly selected from the electoral roll in Southern Tasmania (population 
229,000), with an equal number of men and women. The overall response rate was 
57%. Details on the radiographic and pain assessment have been previously 
described by Saunders et al. 2012. Briefly, a standing anteroposterior semiflexed 
view of the right knee with 15° of fixed knee flexion was performed at baseline in all 
subjects. Western Ontario McMaster OA Index (WOMAC) pain questionnaire scores 
representing the last 30 days were used to classify symptomatic OA. Each knee pain 
item was summed to create a total pain (0–45) score. Prevalent knee pain was 
defined as a total score of 5 or above, corresponding to <91 on a 0-100 scale=worst 
to 100=no pain). Controls were individuals with no knee OA and no hip OA. 
Clearwater OA Study (COS): This study is an ongoing community-based cohort 
study designed to identify risk factors for the development and progression of OA 
(previously described by Wilder et al. 2002). The COS was approved by the 
community-based Institutional Review Board of the Arthritis Research Institute of 
America, an uncompensated, non-employee board that has representation from the 
medical disciplines. Study participants of either gender aged 40 years and older, with 
or without OA, have been included. Subjects completed a questionnaire detailing 
among other things demographics, and a module describing joint symptoms. Weight-
bearing anteroposterior radiographs of both knees were taken at the first and all 
subsequent examinations and graded using an atlas (5). For this study 175 
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individuals with a K/L ≥2 at the first or second visit were included and compared for 
their painful knee status. 
 
Genotyping: 
For all cohort study participants, genomic DNA was extracted from peripheral blood 
leukocytes using standard protocols. Genotyping was carried out by LGC genomics Ltd, 
Hertfordshire UK. SNPs were genotyped using the KASPar chemistry, which is a competitive 
allele-specific PCR SNP genotyping system using FRET quencher cassette oligos. 
Genotyping accuracy, as determined from the genotype concordance between duplicate 
samples was 99.6%.  Six SNPs in the SP receptor (TACR1) gene  were genotyped in the 
GOAL participants rs4853119, rs1861457, rs10168354, rs3755456 and rs3771835 and 
rs11688000. Having found that only rs11688000 was nominally associated with pain 
in OA in this discovery cohort this SNP was subsequently genotyped in the four 
replication cohorts. All variants were in Hardy Weinberg Equilibrium (Table 1,Table 2) 
in the discovery and replication cohorts.  
Statistical analysis: 
Logistic regression analysis was used to test genotype data for an association with 
a) symptomatic OA versus controls, b) asymptomatic OA versus controls and c) 
symptomatic OA versus asymptomatic OA. 
All analyses were run unadjusted and then adjusted for a) age, sex and BMI and, for 
data used in fixed effects meta-analysis using results from logistic regression 
analysis in each of the five groups, b) age, sex, BMI and maximum knee K/L grade. 
Maximum knee K/L grade was the maximum K/L grade for either right or left knee. In 
sensitivity analysis using the GOAL cohort, logistic regression analyses were also 
adjusted for depression status, alongside age, sex, BMI and maximum K/L grade. 
The statistical package R (version 3.0.2) was used for these analyses. Any further 
adjustments are indicated in the results tables where applicable. 
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The “meta” package for R was used to run a meta-analysis to test if any significant 
findings from the discovery analysis replicated in the other groups and give an 
overall effect. 
These six SNPs represent 52.5% of the variation in the TACR1 gene with r2≥0.6 and 
MAF 5-50% (https://snpinfo.niehs.nih.gov/snpinfo/snptag.htm). 
Results 
Descriptive statistics of the study cohorts are shown in Table 1. Participants with 
knee pain generally had higher BMI, and were more likely to display KL≥3 than those 
with radiographic OA without knee pain, but groups overall had similar ages and sex 
distributions. 
It should be noted that KL grades were higher in the GOAL study, likely reflecting 
differences in the natures of the populations being sampled. 
A nominally significant association was seen between rs11688000 genotype and 
symptomatic versus asymptomatic OA in the GOAL group in both the unadjusted 
analysis: OR=0.84 95% 0.71-0.99, and after adjusting for age, sex and BMI (Table 
2). 
No significant associations were seen for any of these SNPs between symptomatic 
OA versus controls, or asymptomatic OA versus controls (Table 2). 
The association of rs11688000 with symptomatic versus asymptomatic OA achieved 
p<0.004 in all replication cohorts combined. The direction of the genetic effect was 
the same in all cohorts with the G (minor) allele being associated with lower risk of 
symptomatic knee OA. 
A fixed effects meta-analysis using results from the unadjusted logistic regression 
analysis in each of the five groups gave a final effect of: OR=0.80 95% 0.70-0.91, 
p=8.66x10-4 (Figure 1A). Using the results from the fully adjusted logistic regression 
analysis (adjusted for age, sex, BMI and maximum KL grade) gave a result of: 
OR=0.79 95% 0.68-0.90, p=9.90x10-4 (Figure 1B). There was no significant 
heterogeneity between the five groups studied (I2=0%). After adjusting for multiple 
testing (six SNPs by three phenotypes) the necessary Bonferroni corrected p-value 
remained significant at 0.0027.  
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Finally, we tested whether the association between TACR1 and OA pain might be 
confounded by depression. Depression status was not available for the replication 
cohorts but in the discovery cohort the odds ratio for SNP between people with 
radiographic OA with or without pain in the GOAL cohort following adjustment for 
age, sex, BMI, KL grade and depression was OR=0.84 95% CI 0.70-1.00, essentially 
unchanged from the OR adjusted for age, sex, BMI and KL grade alone (Table 2). 
 
Discussion and conclusions 
This study found a genetic effect on the risk of symptomatic OA versus 
asymptomatic OA given by the rs11688000 SNP in the TACR1 gene. To our 
knowledge, this is the first study to show an effect of variation in the TACR1 gene on 
chronic pain. 
We found no significant associations between symptomatic OA cases and controls 
or between asymptomatic OA cases and controls. A potential explanation for this is 
that the controls were selected based on X rays and not on their knee pain status, 
and thus may include individuals with other forms of pain. 
This study extends previously published work on the relevance of SP and its 
receptor in OA and OA pain (Marshall et al. 1990; Lindh et al. 1997; Zubryzcka and 
Janecka 2000; Im et al. 2008) by showing significant effects of variants in the SP 
receptor gene on the risk of painful (symptomatic) OA. The results of this study 
support the involvement of TACR1 gene in OA pain, and extend results from 
previous candidate gene studies on differences in pain perception and sensitivity. 
Variants in the TRPV1 (rs8065080), COMT (rs4680), SCN9A (rs6746030) and 
PACE4 (rs900414) genes have been previously implicated in the risk of symptomatic 
versus asymptomatic OA (reviewed in (Warner and Valdes 2016)), in that individuals 
with a particular allele at variants in these genes were more or less likely to report 
symptomatic OA versus asymptomatic OA, highlighting the role of genetics in the 
risk of clinical OA (Warner and Valdes 2016). A variant in the TACR1 gene has also 
been associated with responses to nociceptive stimuli in experimental pain in people 
without arthritis (Storm et al. 2013) indicating that this gene might contribute to 
variations in pain processing between individuals (Storm et al. 2013). Our data lead 
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us to suggest that variations in TACR1 might partially explain differences in pain 
experience amongst people with The rs11688000 SNP A 
allele that was associated with increased risk of pain in our study, has also identified 
as being suggestively associated with alcohol dependence (AD; n=326) (Blaine et al. 
2013) further suggesting possible contributions to processes within the central 
nervous system.  
 
This SNP is intergenic (noncoding) and its function is not known. However intergenic 
SNPs can potentially influence transcription and therefore affect gene function. 
Functional work on this variant is required to follow-up these findings and put them 
into a biological context. 
It should be noted also that both the association we report with symptomatic OA and 
those previously reported for the TACR1 gene do not achieve genome wide 
significance (p < 5 x 10[-8]) and therefore variants in this gene do not appear to have 
sufficiently large effects in depression and PTSD (Lewis et al. 2010, Logue et al. 
2013)(add refs to GWASes here). On the other hand, very little is known about the 
molecular determinants of interindividual differences to pain in OA and the 
association reported here raises the possibility that modulating TACR1 activity 
pharmacologically could be used as a therapy for OA pain. An early randomised 
controlled trial failed to demonstrate analgesic efficacy for the NK1 receptor 
antagonist lanepitant in OA, but investigators argued that this was possibly due to 
poor central nervous system penetration of the compound and the heterogeneity 
seen in groups of people with OA (Goldstein et al. 2000). Despite the involvement of 
SP and its receptor in numerous physiological processes, there is at present an 
incomplete understanding of the therapeutic potential of NK1 receptor antagonists 
(Brain and Cox 2006).  
TACR1 is widely expressed in the body, including in both the central and peripheral 
nervous system (Almeida et al. 2004, Pinto et al. 2004), suggesting that further trials 
are needed to investigate how central and peripheral NK1 receptors can be better 
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targeted. For example, peripheral and central pain are both seen in people with OA 
and these different pathologies require different treatment and research approaches. 
Studies have shown that SP is an important component of the inflammatory 
response at peripheral sites, in conjunction with other factors (Pantaleo et al. 2010). 
One aspect that must be considered regarding the potential efficacy of  NK1 receptor 
antagonists  as analgesics is the age dependent effect of SP in pain. There is 
evidence from animal models showing that  NK1 receptor modifies the development 
of symptoms and that substance P modifies the sensitization of joint receptors 
receptors in an age dependent manner.  (Cruce et al 2001, McDougal and Scheulert 
2006). Although, our results are adjusted for age it is possible that any compounds 
targeting substance P for OA pain could have different efficiacies depending on age 
and this may explain some of the lack of efficacy seen in previous studies.  
More recently, NK1 receptor antagonists have been shown to be efficacious or have 
strong potential for use in various neurobehavioral indications, such as depression, 
stress, anxiety, alcoholism and post-traumatic stress disorder (summarised in 
(Hallberg 2015)). For example some NK1 receptor antagonists (such as orvepitant) 
display good penetration of the CNS, and can improve symptoms of depression and 
improve sleep quality (Ratti et al. 2013). Use of LY686017, another NK1 receptor 
antagonist, was associated with lower alcohol consumption suppressed alcohol 
cravings in recovering alcoholics (George et al. 2008). Given that the same variant 
associated with higher risk of alcoholism in the TACR1 gene is also associated with 
higher risk of OA pain, this suggests the possibility that the same antagonists may 
have a positive effect on OA pain. It remains possible that NK1 receptors are 
important in OA pain only for a subgroup of the population, for example those with 
the associated TACR1 variants, and further research should also determine whether 
TACR1 variants predict analgesic response to NK1 antagonists in knee OA. 
We note several study limitations. In this study we covered only 52.5% of the 
variation within the TACR1 gene hence we may have missed stronger associations 
at other variants within this gene. Additionally, this variant has no currently identified 
functional correlate, so the mechanism of its effect in alcohol dependence and pain 
in OA is unknown. Importantly, the SNP identified by us, as other variants associated 
to psychiatric traits in this gene, do not derive from genome wide association studies 
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achieving the critical p-value of 5 x 10[-8]. Such a stringent level is achieved only in 
the presence of very strong genetic effects and or very large sample sizes which 
were not available in our study.  
Other potential limitations include the radiographic assessment of knee OA which 
was limited just to the tibio-femoral compartments without assessment of the patello-
femoral compartment which is commonly affected by OA and may also associate 
with pain and the fact that the study included only Caucasian participants, as is 
common in genetic studies, and therefore the findings might not be applicable to 
groups from other ethnic backgrounds. 
Depression was a potential confounder although in the discovery cohort, where 
available data permitted classification for depression, the association of rs11688000 
and symptomatic versus asymptomatic OA was unaffected by for depression. 
The NK1 receptor encoded by TACR1 is a potential therapeutic target for which small 
molecule antagonists have already been developed for use in man. Further research 
is needed to determine the mechanisms by which NK1 receptor variants might 
influence OA pain, and their relative importance compared to other genetic or 
environmental factors for individuals with knee or other forms of arthritis. For 
example, there are currently no published genome-wide studies comparing 
symptomatic versus asymptomatic OA. The precise mechanisms underlying the 
asymptomatic presentation of OA require further study. 
In conclusion, the results of this study support a role of SP and its receptor in pain 
experienced by some people with OA. NK1 receptor antagonists might have potential 
for the treatment of pain, at least in subgroups of people with OA who carry the 
rs11688000 allele studied here  
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Table 1: Descriptive statistics for symptomatic OA and asymptomatic OA 
participants in each study group 
Cohort name 
Genetics of 
Osteoarthritis 
and Lifestyle  
Hertfordshire 
Cohort Study  
Chingford 
study 
Tasmanian 
Older Adult 
Cohort 
Clearwater 
Osteoarthritis 
Study 
Cohort acronym GOAL HCS Chingford TASOAC COS 
Reference for 
cohort details 
(Valdes et al 
2011) 
(Ahie Sayer et 
al 2004) 
(Hart  & 
Spector 
1993) 
(Saunders 
et al 2011) 
(Wilder  et al 
2002) 
Country of origin UK UK UK Australia USA 
rs11688000   
HWE1 p-value 
 0.94 0.22 0.72 0.23 
Symptomatic knee 
OAa  
n=1232 n=86 n=71 n=94 n=83 
Mean age (SD) 68.4 (7.2) 65.3 (2.8) 55.7 (5.8) 65.0 (7.2) 64.8 (7.8) 
% Female 47.89% 45.30% 100% 41.50% 67.50% 
Mean BMI kgm-2 
(SD) 
31.2 (5.4) 29.7 (5.4) 26.7 (3.4) 31.3 (6.3) 28.7 (5.0) 
% K/L≥3 95.62% 39.53% 43.66% 42.55% 38.55% 
TACR1 rs11688000 
G  allele frequency 
0.361 0.337 0.324 0.298 0.337 
      
Asymptomatic 
knee OAa 
n=383 n=44 n=220 n=145 n=92 
Mean age (SD) 69.0 (6.8) 65.2 (2.4) 55.7 (5.9) 65.7 (7.6) 63.8 (9.4) 
% Female 43.90% 31.80% 100% 56.55% 60.90% 
Mean BMI kgm-2 
(SD) 
28.9 (4.9) 28.4 (4.0) 26.3 (4.4) 28.1 (4.3) 26.4 (5.0) 
% K/L≥3 67.40% 15.90% 28.18% 24.83% 20.65% 
TACR1 rs11688000 
G  allele frequency 
0.401 0.398 0.388 0.372 0.413 
1Hardy Weinberg equilibrium p-value 
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Table 2: The results of logistic regression analysis showing the association of each of the six TACR1 SNPs with three measures of 
symptomatic versus asymptomatic OA. All analyses are adjusted for age, sex and BMI 
 
*p<0.05 
 
SNP ID BP MAF 
Effect 
allele/No 
effect 
Gene 
location 
Symptomatic OA 
versus controls 
OR (95%) 
Symptomatic OA versus 
asymptomatic OA 
ORi(95%) 
Controls versus 
asymptomatic OA 
OR (95%) 
rs4853119 75416296 0.745 T/C Intron 0.95 (0.80-1.13) 1.05 (0.88-1.26) 0.93 (0.75-1.16) 
rs1861457 75323267 0.330 T/C Intron 0.89 (0.76-1.04) 0.98 (0.82-1.17) 0.91 (0.74-1.11) 
rs10168354 75382710 0.572 T/C Intron 1.12 (0.96-1.30) 0.95 (0.80-1.12) 1.10 (0.90-1.34) 
rs3755456 75287819 0.855 T/C Intron 0.89 (0.72-1.11) 1.20 (0.96-1.51) 0.77 (0.59-1.00) 
rs3771835 75374043 0.453 T/C Intron 0.92 (0.79-1.07) 1.04 (0.88-1.23) 0.89 (0.73-1.08) 
rs11688000 75293157 0.368 G/A Intron 1.04 (0.89-1.22)  0.84 (0.70-1.00)* 1.19 (0.97-1.46) 
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Figure 1: Forest plot showing the results of a fixed-effects meta-analysis of the discovery 
group (GOAL) and the four replication groups used in the analysis of rs11688000 G allele in 
the TACR1 gene and its association with symptomatic OA versus asymptomatic OA (A) and 
after adjustment for age, sex, BMI and K/L grade (B) 
 
